Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CocoaVia’s “catch”?

This article was originally published in The Tan Sheet

Executive Summary

Supplements are a better way for consumers to get plant sterols than Mars' CocoaVia brand of fortified chocolate, according to the February Harvard Heart Letter. "Capsules don't deliver extra calories or saturated fat," the consumer newsletter points out. The Letter also recommends consumers choose either supplements or healthier foods like tea, apples, raspberries and red wine as their source for flavanols. According to the Letter, unless an individual cuts calories "somewhere else" or walks an extra 45 minutes a day, the added calories from the twice-daily recommended intake of CocoaVia would lead to a 20 lb. weight gain in one year. The product also contains 36% of an individual's daily recommended limit for saturated fat. "That's more than enough to counteract any benefits from sterols and flavanols," the publication concludes. Mars recommends eating CocoaVia as a "substitute for other foods without heart health benefits" and notes that the product, "like any food, should be consumed in moderation as part of an overall healthy diet"...

You may also be interested in...

Bayer Confident CureVac COVID Pact Will Be A Success

CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.

EMA Works On Defining Metadata From RWD Sources

As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.

UCB And Microsoft Expand AI Tie-Up Beyond COVID-19

Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts